Collegium Pharmaceutical agreed to acquire AZSTARYS for $650 million in cash from privately held Corium Therapeutics. The deal adds a marketed ADHD product to Collegium's commercial portfolio, representing a material cash deployment that could meaningfully affect revenue mix for the company. Given the deal size relative to typical small- to mid-cap biopharma transactions, the news is likely to move COLL shares modestly.
Collegium Pharmaceutical agreed to acquire AZSTARYS for $650 million in cash from privately held Corium Therapeutics. The deal adds a marketed ADHD product to Collegium's commercial portfolio, representing a material cash deployment that could meaningfully affect revenue mix for the company. Given the deal size relative to typical small- to mid-cap biopharma transactions, the news is likely to move COLL shares modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
